PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra
Completed
Magee-Womens Hospital
Phase 4
2005-06-01
This is an open-label prospective, multicenter, randomized trial to compare continuation
rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred
women will be recruited at 9 centers nationwide to be randomly assigned to use either the
NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently
stopped the pill and be relatively satisfied with oral contraceptive use to qualify for
enrollment. Two visits and two phone calls will be required.
PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra
Completed
Organon
Phase 4
2005-06-01
This is an open-label prospective, multicenter, randomized trial to compare continuation
rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred
women will be recruited at 9 centers nationwide to be randomly assigned to use either the
NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently
stopped the pill and be relatively satisfied with oral contraceptive use to qualify for
enrollment. Two visits and two phone calls will be required.
PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra
Completed
University of Pittsburgh
Phase 4
2005-06-01
This is an open-label prospective, multicenter, randomized trial to compare continuation
rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred
women will be recruited at 9 centers nationwide to be randomly assigned to use either the
NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently
stopped the pill and be relatively satisfied with oral contraceptive use to qualify for
enrollment. Two visits and two phone calls will be required.
Oral Contraceptive Pills Compared to Vaginal Rings
Completed
Organon
N/A
2003-04-01
The purpose of this study is to determine whether teens and young women would prefer the
Nuvaring to oral contraceptive pills after having tried both methods.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
